Grifols, S.A. (GRF.MC)

12,35 -0,17 (-1,36%) Börsenschluss: 05:35PM CEST

Grifols, S.A.

Avinguda de la Generalitat, 152
Parc de Negocis Can Sant Joan Sant Cugat del Valles
Barcelona 08174
Spain
34 93 571 05 00
https://www.grifols.com

Sektor(en): Healthcare
Branche: Drug Manufacturers—General
Vollzeitmitarbeiter: 23.631

Leitende Angestellte

Name	Titel	Zahlen	Ausgeübt	Geburtsjahr
Mr. Thomas H. Glanzmann	CEO & Exec. Chairman	150k	N/A	1958
Mr. Raimon Grifols Roura	Chief Corp. Officer & Vice-Chairman	1,04M	N/A	1964
Mr. Víctor Grifols Deu	COO & Director	1,04M	N/A	1977
Mr. Alfredo Arroyo Guerra	CFO & VP	N/A	N/A	1958
Mrs. Eva Bastida Tubau	Corp. VP and Director of Scientific & Medical Affairs	N/A	N/A	N/A
Ms. Nuria Pascual Lapeña	VP of Corp. Treasury, Risk Management Investor Relation & Sustainability Officer	N/A	N/A	1964
Mr. David Ian Bell	Chief Corp. Devel., Legal & Data Protection Officer	N/A	N/A	1954
Mr. Mateo Florencio Borrás Humbert	Corp. VP & Chief HR Officer	N/A	N/A	1956
Ms. Maria Teresa-Rioné Llano	Chief Communications Officer	N/A	N/A	1965
Ms. Montserrat Gaja Llamas	Chief HR Officer	N/A	N/A	1965

Die Beträge haben den Stand 31. Dezember 2022 und Kompensationswerte gelten für das letzte Geschäftsjahr bis zu diesem Datum. Der Lohn umfasst Gehalt, Boni usw. „Ausgeübt“ entspricht dem Wert von Optionen, die im Lauf des Geschäftsjahrs ausgeübt werden. Währung in EUR.

Beschreibung

Grifols, S.A. operates as a plasma therapeutic company in Spain, the United States, Canada and internationally. The Biopharma segment provides plasma derivatives products, including Gamunex/Gamunex-C Immune Globulin Injection, Flebogamma Immune Globulin Intravenous, Xembify Immune Globulin Subcutaneous solution, HyperRAB Rabies Immune Globulin, Prolastin/Prolastin-C/Prolastin-C Liquid/Prolasplan/Prolastina/Pulmolast/Lynspad Alpha 1-Proteinase Inhibitor, Fanhdi and Alphanate, Antihemophilic Factor/von Willebrand factor Complex, Koate-DVI Antihemophilic Factor, Albutein/Albutein Flexbag/ Human Albumin Grifols/Plasbumin Albumin, and Vistaseal/Veraseal; and Tavlesse, a non-plasma derivative medicinal product. The Diagnostic segment offers transfusion medicine, which includes Procleix Panther systems/Procleix Panther with Automation Ready technology, Automated NAT blood screening systems, assays, software, WADiana/Erytra/Erytra Eflexys analyzers, BLOODchip ID/IDCore/IDHPA/IDRHD/IDCORE/BIDS, and antigens; and clinical and diagnostics products, such as Promonitor and Alpha1D. The Bio Supplies segment provides human biological materials for life sciences research and the development and manufacturing of pharmaceutical and diagnostic products. The Others segment offers healthcare solutions, which provides services and manufactures products, including parenteral solutions, robotics, and software used by hospitals, blood banks, plasma collection centers and other healthcare systems. The company's products and services are used by healthcare providers to diagnose and treat patients with hemophilia, immune deficiencies, infectious diseases, and other medical conditions. Grifols, S.A. has collaboration agreements with Canadian Blood Services for the processing of other plasma-derived products, and with GIANT and GigaGen to develop recombinant polyclonal immunoglobulin therapies. The company was founded in 1940 and is headquartered in Barcelona, Spain.

Corporate Governance

Grifols, S.A.s ISS Governance QualityScore, Stand 1. September 2023, lautet 3. Die grundlegenden Scores sind Audit: 2, Vorstand: 5, Shareholderrechte: 9, Kompensation: 3.

Corporate-Governance-Bewertungen von Institutional Shareholder Services (ISS). Die Werte geben den Zehntelwert im Verhältnis zum Index oder zur Region an. Ein Zehntelwert von 1 zeigt geringeres Governance-Risiko, 10 höheres Governance-Risiko.